Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Anti-amyloid beta (Aβ) monoclonal antibody

or Antiparkinsonian

Use the filters below to narrow your results.

None (3) · Amantadine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Butorphanol (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Entacapone (1) · Ethylmorphine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Levodopa (1) · Levorphanol (1) · Meperidine (1) · Nalbuphine (1) · Opicapone (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Tapentadol (1) · Tolcapone (1) · Trihexyphenidyl (1)

None (6) · (multiple, generic dominant) (1) · Aduhelm (1) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cogentin (1) · Comtan (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dostinex (1) · Duragesic (1) · Eldepryl (1) · Kisunla (1) · Leqembi (1) · Neupro (1) · Nubain (1) · Nucynta (1) · Ongentys (1) · Opana (1) · Parlodel (1) · Sinemet (1) · Stadol (1) · Symmetrel (1) · Talwin (1) · Tasmar (1) · Vicodin (1) · Xadago (1)

None (2) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) · Irreversible selective MAO-B inhibitor (2) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective M1 muscarinic antagonist (1)

None (31) · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (31) · 10 mg/kg IV every 2 weeks (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

None (31) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 350 mg/20 mL vial for IV infusion (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

None (31) · 10 mg/kg q2w (1) · 1400 mg q4w (1) · 360 mg/day (1) · Withdrawn 2024 (1)

None (31) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (2) · PO (only formulation marketed in the US). (1)

None (31) · 30–60 min (PO) (1) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · PET Aβ reduction over months (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)

None (31) · 4–6 hours (1) · Ongoing dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1) · Withdrawn (1)

None (31) · 2.5–3 hours (1) · ~12.1 days (1) · ~25 days (1) · ~5-7 days (1)

None (31) · 100% (IV) (3) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (31) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Discontinued/withdrawn (1) · Limited data (2)

None (31) · Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · Withdrawn from US market January 2024 (1)